Table of Content

1 Report Overview
1.1 Crigler-Najjar Syndrome Drug Definition
1.2 Market by Type
1.2.1 Global Crigler-Najjar Syndrome Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 ALXN-1540
1.2.3 AT-342
1.2.4 HepaStem
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Crigler-Najjar Syndrome Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Crigler-Najjar Syndrome Drug Sales
2.1 Global Crigler-Najjar Syndrome Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Crigler-Najjar Syndrome Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Crigler-Najjar Syndrome Drug Revenue by Region
2.3.1 Global Crigler-Najjar Syndrome Drug Revenue by Region (2018-2024)
2.3.2 Global Crigler-Najjar Syndrome Drug Revenue by Region (2024-2034)
2.4 Global Crigler-Najjar Syndrome Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Crigler-Najjar Syndrome Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Crigler-Najjar Syndrome Drug Sales Quantity by Region
2.6.1 Global Crigler-Najjar Syndrome Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Crigler-Najjar Syndrome Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Crigler-Najjar Syndrome Drug Sales Quantity by Manufacturers
3.1.1 Global Crigler-Najjar Syndrome Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Crigler-Najjar Syndrome Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Crigler-Najjar Syndrome Drug Sales in 2022
3.2 Global Crigler-Najjar Syndrome Drug Revenue by Manufacturers
3.2.1 Global Crigler-Najjar Syndrome Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Crigler-Najjar Syndrome Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Crigler-Najjar Syndrome Drug Revenue in 2022
3.3 Global Crigler-Najjar Syndrome Drug Sales Price by Manufacturers
3.4 Global Key Players of Crigler-Najjar Syndrome Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Crigler-Najjar Syndrome Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Crigler-Najjar Syndrome Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Crigler-Najjar Syndrome Drug, Product Offered and Application
3.8 Global Key Manufacturers of Crigler-Najjar Syndrome Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Crigler-Najjar Syndrome Drug Sales Quantity by Type
4.1.1 Global Crigler-Najjar Syndrome Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Crigler-Najjar Syndrome Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Crigler-Najjar Syndrome Drug Revenue by Type
4.2.1 Global Crigler-Najjar Syndrome Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Crigler-Najjar Syndrome Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
4.3 Global Crigler-Najjar Syndrome Drug Price by Type
4.3.1 Global Crigler-Najjar Syndrome Drug Price by Type (2018-2024)
4.3.2 Global Crigler-Najjar Syndrome Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Crigler-Najjar Syndrome Drug Sales Quantity by Application
5.1.1 Global Crigler-Najjar Syndrome Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Crigler-Najjar Syndrome Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Crigler-Najjar Syndrome Drug Revenue by Application
5.2.1 Global Crigler-Najjar Syndrome Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Crigler-Najjar Syndrome Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
5.3 Global Crigler-Najjar Syndrome Drug Price by Application
5.3.1 Global Crigler-Najjar Syndrome Drug Price by Application (2018-2024)
5.3.2 Global Crigler-Najjar Syndrome Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Crigler-Najjar Syndrome Drug Sales by Company
6.1.1 North America Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024)
6.1.2 North America Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024)
6.2 North America Crigler-Najjar Syndrome Drug Market Size by Type
6.2.1 North America Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Crigler-Najjar Syndrome Drug Revenue by Type (2018-2034)
6.3 North America Crigler-Najjar Syndrome Drug Market Size by Application
6.3.1 North America Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Crigler-Najjar Syndrome Drug Revenue by Application (2018-2034)
6.4 North America Crigler-Najjar Syndrome Drug Market Size by Country
6.4.1 North America Crigler-Najjar Syndrome Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Crigler-Najjar Syndrome Drug Revenue by Country (2018-2034)
6.4.3 North America Crigler-Najjar Syndrome Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Crigler-Najjar Syndrome Drug Sales by Company
7.1.1 Europe Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024)
7.2 Europe Crigler-Najjar Syndrome Drug Market Size by Type
7.2.1 Europe Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Crigler-Najjar Syndrome Drug Revenue by Type (2018-2034)
7.3 Europe Crigler-Najjar Syndrome Drug Market Size by Application
7.3.1 Europe Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Crigler-Najjar Syndrome Drug Revenue by Application (2018-2034)
7.4 Europe Crigler-Najjar Syndrome Drug Market Size by Country
7.4.1 Europe Crigler-Najjar Syndrome Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Crigler-Najjar Syndrome Drug Revenue by Country (2018-2034)
7.4.3 Europe Crigler-Najjar Syndrome Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Crigler-Najjar Syndrome Drug Sales by Company
8.1.1 China Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024)
8.1.2 China Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024)
8.2 China Crigler-Najjar Syndrome Drug Market Size by Type
8.2.1 China Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2034)
8.2.2 China Crigler-Najjar Syndrome Drug Revenue by Type (2018-2034)
8.3 China Crigler-Najjar Syndrome Drug Market Size by Application
8.3.1 China Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2034)
8.3.2 China Crigler-Najjar Syndrome Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Crigler-Najjar Syndrome Drug Sales by Company
9.1.1 APAC Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024)
9.2 APAC Crigler-Najjar Syndrome Drug Market Size by Type
9.2.1 APAC Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Crigler-Najjar Syndrome Drug Revenue by Type (2018-2034)
9.3 APAC Crigler-Najjar Syndrome Drug Market Size by Application
9.3.1 APAC Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Crigler-Najjar Syndrome Drug Revenue by Application (2018-2034)
9.4 APAC Crigler-Najjar Syndrome Drug Market Size by Region
9.4.1 APAC Crigler-Najjar Syndrome Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Crigler-Najjar Syndrome Drug Revenue by Region (2018-2034)
9.4.3 APAC Crigler-Najjar Syndrome Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Audentes Therapeutics Inc
11.1.1 Audentes Therapeutics Inc Company Information
11.1.2 Audentes Therapeutics Inc Overview
11.1.3 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Products and Services
11.1.5 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug SWOT Analysis
11.1.6 Audentes Therapeutics Inc Recent Developments
11.2 Genethon SA
11.2.1 Genethon SA Company Information
11.2.2 Genethon SA Overview
11.2.3 Genethon SA Crigler-Najjar Syndrome Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Genethon SA Crigler-Najjar Syndrome Drug Products and Services
11.2.5 Genethon SA Crigler-Najjar Syndrome Drug SWOT Analysis
11.2.6 Genethon SA Recent Developments
11.3 International Stem Cell Corp
11.3.1 International Stem Cell Corp Company Information
11.3.2 International Stem Cell Corp Overview
11.3.3 International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 International Stem Cell Corp Crigler-Najjar Syndrome Drug Products and Services
11.3.5 International Stem Cell Corp Crigler-Najjar Syndrome Drug SWOT Analysis
11.3.6 International Stem Cell Corp Recent Developments
11.4 Promethera Biosciences SA
11.4.1 Promethera Biosciences SA Company Information
11.4.2 Promethera Biosciences SA Overview
11.4.3 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Products and Services
11.4.5 Promethera Biosciences SA Crigler-Najjar Syndrome Drug SWOT Analysis
11.4.6 Promethera Biosciences SA Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Crigler-Najjar Syndrome Drug Value Chain Analysis
12.2 Crigler-Najjar Syndrome Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Crigler-Najjar Syndrome Drug Production Mode & Process
12.4 Crigler-Najjar Syndrome Drug Sales and Marketing
12.4.1 Crigler-Najjar Syndrome Drug Sales Channels
12.4.2 Crigler-Najjar Syndrome Drug Distributors
12.5 Crigler-Najjar Syndrome Drug Customers
13 Market Dynamics
13.1 Crigler-Najjar Syndrome Drug Industry Trends
13.2 Crigler-Najjar Syndrome Drug Market Drivers
13.3 Crigler-Najjar Syndrome Drug Market Challenges
13.4 Crigler-Najjar Syndrome Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of ALXN-1540
Table 3. Major Manufacturers of AT-342
Table 4. Major Manufacturers of HepaStem
Table 5. Major Manufacturers of Others
Table 6. Global Crigler-Najjar Syndrome Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Crigler-Najjar Syndrome Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Crigler-Najjar Syndrome Drug Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Crigler-Najjar Syndrome Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Crigler-Najjar Syndrome Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 13. Global Crigler-Najjar Syndrome Drug Sales by Region (2018-2024) & (K Pcs)
Table 14. Global Crigler-Najjar Syndrome Drug Sales Market Share by Region (2018-2024)
Table 15. Global Crigler-Najjar Syndrome Drug Sales by Region (2024-2034) & (K Pcs)
Table 16. Global Crigler-Najjar Syndrome Drug Sales Market Share by Region (2024-2034)
Table 17. Global Crigler-Najjar Syndrome Drug Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 18. Global Crigler-Najjar Syndrome Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Crigler-Najjar Syndrome Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Crigler-Najjar Syndrome Drug Revenue Share by Manufacturers (2018-2024)
Table 21. Global Crigler-Najjar Syndrome Drug Price by Manufacturers 2018-2024 (USD/Pcs)
Table 22. Global Key Players of Crigler-Najjar Syndrome Drug, Industry Ranking, 2021 VS 2022
Table 23. Global Crigler-Najjar Syndrome Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Crigler-Najjar Syndrome Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Crigler-Najjar Syndrome Drug as of 2022)
Table 25. Global Key Manufacturers of Crigler-Najjar Syndrome Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Crigler-Najjar Syndrome Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Crigler-Najjar Syndrome Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 30. Global Crigler-Najjar Syndrome Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 31. Global Crigler-Najjar Syndrome Drug Sales Quantity Share by Type (2018-2024)
Table 32. Global Crigler-Najjar Syndrome Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Crigler-Najjar Syndrome Drug Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Crigler-Najjar Syndrome Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Crigler-Najjar Syndrome Drug Revenue Share by Type (2018-2024)
Table 36. Global Crigler-Najjar Syndrome Drug Revenue Share by Type (2024-2034)
Table 37. Crigler-Najjar Syndrome Drug Price by Type (2018-2024) & (USD/Pcs)
Table 38. Global Crigler-Najjar Syndrome Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 39. Global Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 40. Global Crigler-Najjar Syndrome Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 41. Global Crigler-Najjar Syndrome Drug Sales Quantity Share by Application (2018-2024)
Table 42. Global Crigler-Najjar Syndrome Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Crigler-Najjar Syndrome Drug Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Crigler-Najjar Syndrome Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Crigler-Najjar Syndrome Drug Revenue Share by Application (2018-2024)
Table 46. Global Crigler-Najjar Syndrome Drug Revenue Share by Application (2024-2034)
Table 47. Crigler-Najjar Syndrome Drug Price by Application (2018-2024) & (USD/Pcs)
Table 48. Global Crigler-Najjar Syndrome Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 49. North America Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 51. North America Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 52. North America Crigler-Najjar Syndrome Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 53. North America Crigler-Najjar Syndrome Drug Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Crigler-Najjar Syndrome Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 56. North America Crigler-Najjar Syndrome Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 57. North America Crigler-Najjar Syndrome Drug Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Crigler-Najjar Syndrome Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Crigler-Najjar Syndrome Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Crigler-Najjar Syndrome Drug Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Crigler-Najjar Syndrome Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Crigler-Najjar Syndrome Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 63. North America Crigler-Najjar Syndrome Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 64. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 65. Europe Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 67. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 68. Europe Crigler-Najjar Syndrome Drug Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Crigler-Najjar Syndrome Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 71. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 72. Europe Crigler-Najjar Syndrome Drug Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Crigler-Najjar Syndrome Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Crigler-Najjar Syndrome Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Crigler-Najjar Syndrome Drug Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Crigler-Najjar Syndrome Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 78. Europe Crigler-Najjar Syndrome Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 79. China Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 80. China Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 82. China Crigler-Najjar Syndrome Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 83. China Crigler-Najjar Syndrome Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Crigler-Najjar Syndrome Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 86. China Crigler-Najjar Syndrome Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 87. China Crigler-Najjar Syndrome Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Crigler-Najjar Syndrome Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 90. APAC Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 92. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 93. APAC Crigler-Najjar Syndrome Drug Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Crigler-Najjar Syndrome Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 96. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 97. APAC Crigler-Najjar Syndrome Drug Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Crigler-Najjar Syndrome Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Crigler-Najjar Syndrome Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Crigler-Najjar Syndrome Drug Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Crigler-Najjar Syndrome Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Region (2018-2024) & (K Pcs)
Table 103. APAC Crigler-Najjar Syndrome Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 104. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 105. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 107. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 108. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 111. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 112. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 118. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 119. Audentes Therapeutics Inc Company Information
Table 120. Audentes Therapeutics Inc Description and Overview
Table 121. Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 122. Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Product and Services
Table 123. Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug SWOT Analysis
Table 124. Audentes Therapeutics Inc Recent Developments
Table 125. Genethon SA Company Information
Table 126. Genethon SA Description and Overview
Table 127. Genethon SA Crigler-Najjar Syndrome Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Genethon SA Crigler-Najjar Syndrome Drug Product and Services
Table 129. Genethon SA Crigler-Najjar Syndrome Drug SWOT Analysis
Table 130. Genethon SA Recent Developments
Table 131. International Stem Cell Corp Company Information
Table 132. International Stem Cell Corp Description and Overview
Table 133. International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 134. International Stem Cell Corp Crigler-Najjar Syndrome Drug Product and Services
Table 135. International Stem Cell Corp Crigler-Najjar Syndrome Drug SWOT Analysis
Table 136. International Stem Cell Corp Recent Developments
Table 137. Promethera Biosciences SA Company Information
Table 138. Promethera Biosciences SA Description and Overview
Table 139. Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 140. Promethera Biosciences SA Crigler-Najjar Syndrome Drug Product and Services
Table 141. Promethera Biosciences SA Crigler-Najjar Syndrome Drug SWOT Analysis
Table 142. Promethera Biosciences SA Recent Developments
Table 143. Key Raw Materials Lists
Table 144. Raw Materials Key Suppliers Lists
Table 145. Crigler-Najjar Syndrome Drug Distributors List
Table 146. Crigler-Najjar Syndrome Drug Customers List
Table 147. Crigler-Najjar Syndrome Drug Market Trends
Table 148. Crigler-Najjar Syndrome Drug Market Drivers
Table 149. Crigler-Najjar Syndrome Drug Market Challenges
Table 150. Crigler-Najjar Syndrome Drug Market Restraints
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Crigler-Najjar Syndrome Drug Product Picture
Figure 2. Global Crigler-Najjar Syndrome Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Crigler-Najjar Syndrome Drug Market Share by Type in 2022 & 2034
Figure 4. ALXN-1540 Product Picture
Figure 5. AT-342 Product Picture
Figure 6. HepaStem Product Picture
Figure 7. Others Product Picture
Figure 8. Global Crigler-Najjar Syndrome Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Crigler-Najjar Syndrome Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Crigler-Najjar Syndrome Drug Report Years Considered
Figure 14. Global Crigler-Najjar Syndrome Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Crigler-Najjar Syndrome Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Crigler-Najjar Syndrome Drug Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Crigler-Najjar Syndrome Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Crigler-Najjar Syndrome Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Crigler-Najjar Syndrome Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Crigler-Najjar Syndrome Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Crigler-Najjar Syndrome Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Crigler-Najjar Syndrome Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Crigler-Najjar Syndrome Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Crigler-Najjar Syndrome Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Crigler-Najjar Syndrome Drug Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Crigler-Najjar Syndrome Drug Revenue in 2022
Figure 32. Crigler-Najjar Syndrome Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Crigler-Najjar Syndrome Drug Revenue Market Share by Company in 2022
Figure 38. North America Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Company in 2022
Figure 39. North America Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Crigler-Najjar Syndrome Drug Revenue Share by Country (2018-2034)
Figure 44. North America Crigler-Najjar Syndrome Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Company in 2022
Figure 48. Europe Crigler-Najjar Syndrome Drug Revenue Market Share by Company in 2022
Figure 49. Europe Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Crigler-Najjar Syndrome Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Crigler-Najjar Syndrome Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Company in 2022
Figure 61. China Crigler-Najjar Syndrome Drug Revenue Market Share by Company in 2022
Figure 62. China Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Company in 2022
Figure 67. APAC Crigler-Najjar Syndrome Drug Revenue Market Share by Company in 2022
Figure 68. APAC Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Crigler-Najjar Syndrome Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Crigler-Najjar Syndrome Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Crigler-Najjar Syndrome Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Crigler-Najjar Syndrome Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Crigler-Najjar Syndrome Drug Value Chain
Figure 93. Crigler-Najjar Syndrome Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed